The Latest Research Progress of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients --Review.
10.19746/j.cnki.issn.1009-2137.2023.04.047
- Author:
Xiao-Sui LING
1
;
Hai-Ping HE
2
;
Li-Hua ZHANG
1
;
Fan LI
1
Author Information
1. The Affiliated Hospital of Kunming University of Science and Technology; Department of Hematology, the First People's Hospital of Yunnan Province, Kunming 650032, Yunnan Province, China.
2. The Affiliated Hospital of Kunming University of Science and Technology; Department of Hematology, the First People's Hospital of Yunnan Province, Kunming 650032, Yunnan Province, China. E-mail: 2398230256@qq.com.
- Publication Type:Journal Article
- Keywords:
bone marrow microenvironment;
cytokines;
mesenchymal stem cells;
multiple myeloma;
signaling pathways
- MeSH:
Humans;
Multiple Myeloma/pathology*;
Osteogenesis;
Mesenchymal Stem Cells;
Cell Differentiation;
Bone Marrow/metabolism*;
Bone Marrow Cells/metabolism*;
Tumor Microenvironment
- From:
Journal of Experimental Hematology
2023;31(4):1233-1236
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a malignant proliferative disease of plasma cells. Bone marrow mesenchymal stem cells (MSC) play an important role in the progression of MM. Compared with normal donor derived MSC (ND-MSC), MM patients derived MSC (MM-MSC) exhibit abnormalities in genes, signaling pathways, protein expression levels and cytokines secreted by themselves. Moreover, the exosomes of MM-MSC can interact with the bone marrow microenvironment. The above reasons can lead to MM cell proliferation, chemoresistance, impaired osteogenic differentiation of MM-MSC, and affect the immunomodulatory capacity of MM patients. In order to further understand the pathogenesis and related influencing factors of MM, this paper reviews the latest research progress of MM-MSC.
